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Background: One of the major pathophysiologies in advanced chronic obstructive pulmonary
disease (COPD) has been attributed to systemic inflammation. Meta-analysis of the 2005 Co-
chrane Database concluded the effect of nutritional supplementation alone on stable COPD
was insufficient to promote body weight gain or exercise capacity. The aim of this study was
to investigate the effectiveness of nutritional supplementation therapy using a nutritional
supplement containing whey peptide with low-intensity exercise therapy in stable elderly
patients with COPD.
Method: In stable elderly COPD patients with %IBW and %FEV1 of less than 110 and 80%, respec-
tively, anti-inflammatory nutritional supplementation therapy was added to low-intensity
exercise therapy. Thirty-six COPD patients were divided into those with and those without
the ingestion of an anti-inflammatory nutritional supplement containing whey peptide, which
exhibited an anti-inflammatory effect. These two groups were designated as the nutritional
support and the control groups, respectively. The body composition, skeletal muscle strength,
exercise tolerance, health-related QOL (HRQOL), and inflammatory cytokines were evaluatedght; FM, fat mass; %AC, %arm circumference; PImax, maximum inspiratory mouth pressure; PEmax,
; 6MWD, 6-minute walking distance; WBI, weight bearing index; CRQ, chronic respiratory disease
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Effect of anti-inflammatory supplementation with whey peptide 1527before and three months after nutritional support combined with exercise therapy in both the
nutritional support group and the control group.
Results: In the nutritional support group, the body weight, %IBW, FM, energy intake, %AC, Alb,
PImax, PEmax, 6MWD, WBI, emotional function, and CRQ total were significantly increased,
and the levels of hsCRP, IL-6, IL-8, and TNF-a were reduced significantly, while no significant
change was noted in any item of physiological evaluation or any biomarker in the control
group.
Conclusion: Concomitant use of a anti-inflammatory nutritional supplement containing whey
peptide, which exhibits an anti-inflammatory effect, with exercise therapy in stable elderly
COPD patients with %IBW< 110% and %FEV1< 80% may not only increase body weight but
may also inhibit systemic inflammation and thus improve exercise tolerance and HRQOL.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Advanced chronic obstructive pulmonary disease (COPD) is
understood as a systemic inflammation mediated by ciga-
rette smoking and air pollution, and subsequently induced
inflammatory cytokines, such as tumor necrosis factor
(TNF)-a, interleukin (IL)-6, and IL-8.1,2 The involvement of
these inflammatory cytokines and endocrine hormones has
been shown to be related to the pathology of the reduction
in exercise tolerance represented by skeletal myopathy and
health-related QOL (HRQOL) in COPD patients.3 According
to the global initiative for chronic obstructive lung disease
(GOLD),4 both body mass index (BMI) and lean body mass
(LBM) or fat-free mass (FFM) were reduced in about 25% of
moderate-severe COPD cases. Malnutrition in COPD is
considered to aggravate the pathology and promote
complication by lung infection, the cause of acute deteri-
oration,5 for which the importance of nutritional therapy
has recently been suggested.
Evidence for its efficacy even in patients without severe
nutrient deficiency has been obtained, suggesting the
necessity of nutritional supplementation therapy as a part
of pulmonary rehabilitation (PR).1,2 Meta-analysis of the
2005 Cochrane Database6 concluded that the effect of
nutritional supplementation alone on stable COPD was
insufficient to promote body weight gain or exercise
capacity. However, it has been reported that combination
therapy with nutritional supplementation and exercise
training was effective in COPD.7,8 Thus, we used a new anti-
nutritional supplement with whey peptide combined with
low-intensity exercise therapy in stable elderly COPD
patients whose body weight was less than 110% of the
reference body weight (%ideal body weight: %IBW) and the
%forced expiratory volume in 1 s (%FEV1) was less than 80%,
and investigated the effects on body composition, skeletal
muscle strength, exercise tolerance, HRQOL, and inflam-
matory cytokines.Subjects and methods (Table 1, Fig. 1)
Thirty-six stable elderly COPD patients with %IBW <110%
and %FEV1 <80% who underwent low-intensity exercise
therapy following the pulmonary rehabilitation (PR)
program, and who met the diagnostic criteria of the COPDguidelines established by the American Thoracic Society
(ATS),9 were enrolled in the study between June 2009 and
May 2010. Forced expiratory volume in 1 s (FEV1) had to be
less than 70% of the reference value, and the increase in
FEV1 after inhalation of a b2-agonist had to be less than 10%
of the reference value.
There were 34 male and 2 female patients (Table 1). The
mean age was 77.2 5.3 years; %IBW, 91.0 11.4%; forced
vital capacity (FVC), 2.7 0.8 L; %forced expiratory volume
in 1 s (%FEV1), 44.5 16.9%; maximum inspiratory mouth
pressure (PImax), 53.8 22.9 cmH2O; and 6-min walking
distance (6MWD), 330 200 m. The patients were randomly
allocated employing the envelope method to a nutrition
group (active nutritional supplementation therapy with
200 kcal/pack of nutritional supplement twice a day in
addition to normal meals and dietary instruction) and
a control group (normal meals alone with dietary instruc-
tion), and the parameters were evaluated before and
3 months after nutritional support with exercise therapy
(Fig. 1). The randomization was done with a double blind
manner. The daily intake of the nutritional supplement was
confirmed in a diary. Patients with a current cigarette
smoking habit and complication of unstable heart disease,
those for whom the medication was changed during the
study period, those with severe disorders interfering with
exercise including mental diseases and difficulty in oral
ingestion of the nutritional supplement, and those in whom
the condition was acutely aggravated after study initiation
were excluded.
This study was reviewed and approved by the Ethics
Committee of our hospital and Akita University School of
Medicine, and carried out in conformity with the Declara-
tion of Helsinki.10 The objective and content of the study
were orally explained to the participants in addition to
using documents. Written consent was obtained after the
subjects were informed that they could decide whether or
not to participate based on their own free will and that
their privacy would be sufficiently considered.
Assessments (Table 2)
The resting energy expenditure (REE) was measured using
a portable simple calorimeter, Metavine (VINE Co., Tokyo,
Japan).11 The system was calibrated daily before the start
of the experiment. The evaluations were performed at
Table 1 Background of stable COPD patients with %IBW <110% and %FEV1 <80%.
Valuables Thirty-six patients Nutritionþ exercise group Control group P value
Number of cases (male/female) 34/2 15/2 (one dropout) 14/0 (4 dropouts)
MRC 2.1 0.8 2.1 0.7 2.0 0.7 ns
Age, years 77.2 5.3 77.4 5.2 77.1 5.8 ns
Body weight, kg 52.3 7.6 50.8 8.3 54.8 4.4 ns
%IBW, % 91.0 11.4 89.2 11.4 94.1 9.7 ns
FMI, kg/m2 5.1 1.5 4.9 1.4 5.3 1.4 ns
FFMI, kg/m2 15.0 1.3 14.7 1.5 15.4 1.0 ns
REE, kcal 1498 240 1490 247 1499 239 ns
REE/REE pred, kcal/kcal 1.3 0.3 1.4 0.2 1.3 0.2 ns
Energy intake, kcal 1934 306 1843 291 2048 319 ns
hsCRP, mg/l 2.13 2.93 2.78 3.38 1.27 1.74 ns
IL-6, pg/ml 2.50 1.19 2.70 1.37 1.78 0.78 ns
IL-8, pg/ml 1.64 1.28 1.96 1.27 1.50 1.45 ns
TNF-a, pg/ml 1.25 0.38 1.24 0.35 1.15 0.28 ns
FVC, L 2.7 0.8 2.5 0.9 3.0 0.7 ns
FEV1, L 1.1 0.4 1.0 0.4 1.2 0.4 ns
FEV1/FVC, % 39.0 10.6 39.8 11.2 38.9 10.1 ns
%FEV1, % 44.5 16.9 43.4 18.1 48.6 15.2 ns
IC, L 1.9 0.6 1.8 0.6 2.1 0.5 ns
PImax, cmH2O 53.8 22.9 44.4 20.1 67.1 20.3 0.0041
6MWD, m 335 179 322 183 369 167 ns
CRQ total 102 17 103 16 102 19 ns
Abbreviation: MRC, Medical Research Council; %IBW, %ideal body weight; FMI, fat mass index; FFMI, fat-free mass index; REE, resting
energy expenditure; BEE, basal energy expenditure; hsCRP, high-sensitivity C-reactive protein; IL: interleukin; FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 s; IC, inspiratory capacity; PImax, maximum inspiratory mouth pressure; 6MWD, six-
minute walking distance; and CRQ, chronic respiratory disease questionnaire.
1528 K. Sugawara et al.9:00e10:00 in the morning fasting state in order to perform
biochemical tests and REE measurement on fasting. REE
was measured when subjects were comfortably lying on
a bed in the supine position. REE was calculated from
oxygen consumption and carbon dioxide production with an
abbreviated Weir formula.12 Of the physical measurements,
%TSF, %AC, and %AMC were calculated by dividing the
measured values by the means of JARD2001.1353 outpatients of the pulmonary rehabilitation clinic of our hospital 
Stable COPD patients 
36 patients with %IBW<110% and %FEV1<80
Nutrition+Exercise group 18     Control + Exercise group 18  
Evaluation before study initiation       Evaluation before study initiation
Drop out 1          Drop out 4 
17    14 
       Evaluation at 3months after study initiation 
Abbreviation; COPD , chronic obstructive pulmonary disease , %IBW , %ideal body weight , %FEV1
 %forced expiratory volume in one second 
Figure 1 Study protocol.Before and during the last week of nutritional therapy,
patients were asked to register their food intakes over 3
consecutive days in order to assess dietary intake. The
obtained information was coded for computer nutrient
analysis. The nutrient database was derived from the
Standard Tables of Food Composition (The Science and
Technology Agency of Japan, 1982). Dietary intake was
calculated by taking the average intake over 3 days. The
use of dietary records provides a good representation of the
actual food consumption because food intake is averaged
over 3 consecutive days, so the effects of day-to-day vari-
ations are largely removed.11 Total protein, carbohydrate,
and fat intakes are presented as percentages of total
energy intake. The total protein intake is also expressed as
grams per kilogram of bodyweight every 24 h.
For biochemical testing, albumin (Alb), hemoglobin
(Hb), and transferrin (Tf) were measured as nutrition
indices, TNF-a, IL-6, IL-8, and high-sensitivity C-reactive
protein (hsCRP) as inflammatory markers. The level of
hsCRP was assessed by latex turbidimetric immunoassay
(Nittobo Medical; Tokyo, Japan), and the analytical sensi-
tivity of this hsCRP assay is 0.1 mg/L. Serum TNF-a, IL-6,
and IL-8 were measured using commercially available
enzyme-linked immunosorbent assay kits (SRL, Inc., Tokyo,
Japan).
The mouth pressure was measured as respiratory muscle
strength using VITALOPOWER KH-101 (CHEST MI Inc., Tokyo,
Japan) following the method reported by Black and Hyatt.14
For the weight-bearing index (WBI), the maximum isometric
extension and contraction of the quadriceps femoris muscle
Table 2 Evaluation items.
Body composition Biochemical tests
 Height
 Body weight
 Body mass index
(BMIZ body weight (kg)/height (m)2
 %ideal body weight
(%IBWZ body weight (kg)/height (m)2 22 100)
 Fat free mass(FFM)
 FFM index
 Fat mass(FM)
 FM index
 Mid-upper arm circumference (AC)
 %AC
 Triceps skin fold thickness(TSF)
 %TSF
 Mid-upper arm muscle circumference(AMC)
 %AMC
 Nutrition index
Serum albumin
Hemoglobin
Transferrin
 Inflammatory marker
TNF-a(EIA)
IL-6(CLEIA)
IL-8(ELISA)
hsCRP(latex immunoturbidimetric method)
Energy expenditure Evaluation of pulmonary rehabilitation
 Resting energy expenditure(REE)
 REE predict
HarriseBenedict formula
ManZ 66.5þ (13.8 body weight (kg))
þ (5.0 height (cm))(6.8 age)
WomanZ 655.1þ (9.6 body weight (kg))
þ (1.8 height (cm))(4.7 age)
 REE/REE predict
 REE/FFM
 Respiratory muscle strength(PImax and PEmax)
 Weight-bearing index(WBI)
 Six-minute walking distance(6MWD)
 Borg scale before and after 6MWD
 HRQOL(CRQ)
Abbreviation: TNF-a, tumor necrosis factor-a; IL, interleukin; hsCRP, high-sensitivity C-reactive protein; PImax, maximum inspiratory
mouth pressure; PEmax, maximum expiratory mouth pressure; and CRQ, chronic respiratory disease questionnaire.
Effect of anti-inflammatory supplementation with whey peptide 1529were measured at 0 deg/s 80 flexion using HYDRO
MUSCULATOR GT-160 (OG Giken Co., Ltd., Tokyo, Japan).
To measure exercise performance, patients performed
a corridor walk for 6 min according to the ATS guidelines.15
The distance walked in 6 min (6MWD) and the dyspnea scale
were used in the analysis. Patients were not encouraged
during the walk.16
The disease-specific HRQOL was measured using the
Japanese version of the Chronic Respiratory Disease Ques-
tionnaire (CRQ).17 The questionnaire scores four domains:
dyspnea, fatigue, emotion, and mastery. It contains 123
items, of which 62 deal primarily with physical function and
61 with emotional function.17 The results are presented as
mean scores per question in each dimension. The threshold
for clinically significant change for each dimension has been
previously identified as 0.5.18
Nutritional supplement (Table 3)
MEIN (Meiji Dairies Corporation, Tokyo, Japan) was used
as the nutritional supplement in this study. One pack of
MEIN contains 200 kcal/200 ml, and the energy balance
per pack is as follows: protein, 20%; lipids, 25%; sugars,
53.2%; food fibers, 1.8%; and Fisher ratio, 3.7 (Table 3). The
characteristics of MEIN are that whey peptide with an
anti-inflammatory and antioxidant effect, n3 fatty acids(n6:n3Z 2:1), and antioxidant vitamin A, C and E are
enriched.19e21 Patients were directed to take two packs of
MEIN, and the daily intake of the nutritional supplement
was confirmed in a diary.
Exercise program
A multidisciplinary home-based low-intensity PR program16
was used in the present study (Fig. 2). Briefly, breathing
retraining consisted of pursed-lip breathing, diaphragmatic
breathing, and slow deep breathing, in both the supine and
sitting positions. Exercise training included upper and lower
limb exercises, respiratory muscle stretching calis-
thenics,8,22 level walking for least 15 min, and inspiratory
and expiratory muscle exercises using Threshold
(HealthScan Products Inc., Cedar Grove, NJ) set at
a training intensity of 20e30% of the maximal inspiratory
(PImax) and expiratory (PEmax) muscle forces. Patients
also underwent a monthly 45-min education program
including lectures and discussions on respiratory disease,
control of dyspnea, medication and equipment use, nutri-
tion, stress management, relaxation techniques, home
exercises, and the benefits of PR. Patients were strongly
instructed to practice this program daily at home and were
supervised by a physiotherapist every 2 weeks in our
hospital.8,22 A nurse periodically visited each patient at
Table 3 The nutrient ingredient composition of the supplement.
Compositon list (one pack 200 ml)
Proximate composition Aminoacid composition
Energy (kcal) 200 Essential aminoacids (g) 4.5
Protein (g) 10.0 Non-essential aminoacids (g) 5.26
Lipid (g) 5.6 BCAA/AAA 3.7
Glucide (g) 26.6
Dietary fiber 2.4
Vitamin Fattyacid composition
Vitamin A (mgRE) 300 MCT 21
Retinol (mgRE) 120 Palmitic acid 16
b-Carotene (mgRE) 180 Stearinic acid 3
Vitamin E (mg) 10.0 Oleic acid 39
Biotin (mg) 15.0 Linoleic acid 12
Vitamin C (mg) 100 a-Linolenic acid 4
EPA 1.2
DHA 0.8
Other 3
Mineral
Nutrium (mg) 140
Calcium (mg) 160
Zinc (mg) 2.0
Copper (mg) 0.100 n6:n3Z 2:1
BCAA: branched chain aminoacid; AAA: aromatic amino acid; MCT: medium chain triacylglycerol; EPA: eicosapentaenoic acid; and DHA:
docosahexanoic acid.
1530 K. Sugawara et al.home, supervising and providing information regarding the
role of the PR program. Relaxation and stair-climbing
exercises were also carried out under the supervision of
the physiotherapist when the patients visited the hospital.
The overall training intensity was set at 40e50% of the
maximum oxygen consumption.8
Statistics
All parameters (baseline values and change after the
nutritional intervention) were, firstly, checked for
normality of distribution. When variables were normally
distributed and equal variances could be assumed,
Student’s paired t test was applied to compare the differ-
ence between the baseline value and that at 3 months after
nutritional intervention. Student’s unpaired t test was
applied to compare the difference between the nutritionIntroduction  2
Breathing assist    
Breathing assist technique     
Respiratory muscle stretch     
Respiratory muscle strengthening     
Upper and lower limb muscle strengthening    
Aerobic exercise such as walking     
ADL instruction   
Nutritional instruction   
Education (once a month)  
Home visiting by nurse     
Abbreviation; ADL, activities of daily living 
Figure 2 Pulmonary reand control groups. In both tests, the difference was
regarded as significant when the significance level was less
than 5%.
Results
Table 1 lists the baseline parameters of the study group. As
expected, lung function was severely impaired with the
reference values. No baseline differences between the
nutrition with exercise group and the control group were
seen with regards to age, body weight, %IBW, REE, FVC,
FEV1, 6MWD, and CRQ (Table 1).
The daily intake of MEIN was 1.5 0.5 packs in the
nutrition group. Body weight, %IBW, FFM, and %AMC
increased significantly after 12 weeks of anti-inflammatory
nutritional supplementation with exercise therapy
(Table 4). The dietary energy intake and protein intake weeks  4 weeks  6 weeks and after 
    
    
    
    
    
habilitation schedule.
Effect of anti-inflammatory supplementation with whey peptide 1531increased significantly in the nutrition with low-intensity
exercise group compared with those in the control group
(Table 4).
In the nutrition with low-intensity exercise group,
hsCRP, IL-6, IL-8, and TNF-a decreased significantly after
intervention compared with those in the control group
(Table 4). MRC, PImax, 6MWD, quadriceps muscle force,
WBI, and 6MWD increased significantly from baseline
through week 12 in the nutrition with low-intensity exercise
group compared with those in the control group (Table 4,
Fig. 3). Health status, as assessed by the chronic respiratory
questionnaire, improved significantly in the total scores and
the domain of emotional function after intervention in theTable 4 Changes of body composition, muscle force, HRQOL an
Nutritionþ exercise group (nZ 17)
Baseline 12 weeks P value Dratio, %
Weight, kg 50.8 8.3 52.1 8.3 0.002 2.6 3.0
%IBW, % 89.2 11.4 91.5 11.8 0.0019 2.7 3.0
FM, kg 12.7 3.7 14.0 4.0 0.0033 8.6 10.7
FFM, kg 38.0 5.6 38.8 5.4 ns 0.7 2.6
FMI, kg/m2 4.93 1.36 5.43 1.55 0.0028 8.6 10.7
FFMI, kg/m2 14.7 1.5 14.9 1.3 ns 0.7 2.6
Energy intake,
kcal
1843 291 2201 229 <.0001 22.8 16.9
Energy intake,
%pred
84.6 19.3 98.5 16.8 0.0016 21.8 23.0
Protein intake,
g
71.6 13.6 91.7 17.2 <.0001 31.6 25.2
REE, kcal 1490 247 1465 272 ns -1.1 13.1
REE/REE pred 1.42 0.24 1.36 0.17 ns -2.4 13.1
%AC, % 92.3 10.0 94.5 10.5 0.021 2.4 3.7
Albumin, g/dl 4.0 0.3 4.2 0.3 0.0058 3.2 3.9
Transferrin,
mg/dl
240 29.5 239 36.2 ns -0.9 5.8
hsCRP, mg/l 2.68 3.44 1.74 2.01 0.0357 -22.6 41.8
IL-6, pg/ml 2.88 1.48 2.23 1.12 ns -10.6 33.7
IL-8, pg/ml 1.97 1.27 1.07 1.13 0.0332 -32.7 101.3
TNF-a, pg/ml 1.31 0.44 1.08 0.35 0.0053 -12.9 15.3
MRC 2.06 0.75 1.87 0.74 ns -4.4 17.2
PImax, cmH2O 44.4 20.0 60.1 22.1 0.0011 39.2 38.9
PEmax, cmH2O 71.1 32.9 91.4 29.9 0.0107 40.1 55.6
6MWD,m 287 206 368 182 0.004 19.7 24.7
WBI, kg/kg 0.51 0.19 0.55 0.18 0.0169 10.0 13.3
CRQ (HRQOL)
Total 103 16 109 17 0.0033 6.2 7.5
Dyspnea 20.4 6.0 21.7 5.7 ns 10.8 26.8
Fatigue 20.2 3.8 21.6 3.7 ns 8.3 17.9
Emotional
function
38.7 7.3 41.5 6.0 0.0239 8.9 14.4
Mastery 23.2 5.0 23.7 4.7 ns 3.1 9.1
Abbreviation: %IBW, ideal body weight; FM, fat mass; FFM, fat free m
energy expenditure; %AC, % arm circumference; Alb, albumin; hsCRP
necrosis factor; MRC, medical research council; PImax, maximum i
pressure; 6MWD, six-minute walking distance; WBI, weight bearing innutrition with low-intensity exercise group compared with
that in the control group (Table 4, Fig. 3).Discussion
We report herein the results of a pilot study of a combina-
tion of anti-inflammatory nutritional support using supple-
ment contained whey peptide and home-based
low-intensity exercise in elderly patients with COPD. The
combination of anti-inflammatory nutritional supplemen-
tation with whey peptide and low-intensity exercise
training was successful in increasing weight and energyd biomarkers.
Control group (nZ 14) Significant
difference
(between
the group)
Baseline 12 weeks P
value
Dratio, % P value
54.8 4.3 54.6 4.3 ns -0.2 1.4 0.0010
94.1 9.7 93.9 9.3 ns -0.2 1.3 0.0017
13.8 3.2 13.8 2.8 ns 0.6 10.6 0.0486
40.9 2.7 40.8 2.2 ns -0.1 4.4 ns
5.26 1.43 5.23 1.14 ns 0.6 10.6 0.0486
15.4 1.0 15.4 1.1 ns -0.1 4.4 ns
2048 319 2001 333 ns -1.0 18.7 0.0013
92.4 16.8 92.5 25.1 ns 9.5 23.8 ns
88.3 20.3 78.0 12.8 ns -7.3 28.7 0.0006
1499 239 1422 220 ns -6.0 9.9 ns
1.35 0.19 1.29 0.17 ns -5.6 9.9 ns
96.1 8.0 95.4 8.4 ns -0.7 2.4 0.0134
4.1 0.2 4.1 0.2 ns 0.9 6.4 ns
233 33.1 225 254 ns -3.8 5.8 ns
1.27 1.74 1.74 2.07 ns 28.8 100.9 0.0470
1.78 0.78 2.18 0.87 ns 16.5 29.4 0.0268
1.50 1.45 1.77 1.42 ns 1.52 2.30 0.0021
1.15 0.28 1.18 0.28 ns 4.4 20.5 0.0112
2.00 0.68 2.29 0.61 ns 22.6 40.6 0.0339
67.1 20.3 65.4 20.5 ns 0.1 24.1 0.0030
92.5 29.4 97.0 33.6 ns 8.8 36.0 ns
369 167 345 187 ns -7.1 50.8 0.0137
0.72 0.12 0.71 0.15 ns -1.6 9.5 0.0079
102 19 99 21 ns -2.7 13.1 0.0374
20.4 6.5 19.3 6.6 ns -2.7 21.3 ns
20.2 3.8 19.5 6.2 ns -3.6 22.8 ns
40.1 7.6 38.8 9.3 ns -3.9 12.2 0.0097
21.4 5.7 21.6 5.3 ns 3.6 20.8 ns
ass; FMI, fat mass index; FFMI, fat free mass index; REE, resting
, high sensitivity C reactive protein; IL, interleukin; TNF, tumor
nspiratory mouth pressure; PEmax, maximum expiratory mouth
dex; and CRQ, chronic respiratory disease questionnaire.
Figure 3 Percentage change from the baseline values.
1532 K. Sugawara et al.intake as well as exercise capacity and HRQOL in our
patients. Moreover, major inflammatory cytokines
decreased significantly after anti-inflammatory nutritional
supplementation with low-intensity exercise training. This
study suggests that there is a potential role for the
combination of anti-inflammatory nutritional support with
whey peptide and low-intensity exercise in the manage-
ment of patients with COPD.
High inflammatory cytokine levels such as IL-6, IL-8, and
TNF-a have been shown to be characteristics of advanced
muscle loss and associated with weight loss.23,24 The serum
TNF-a level was high in COPD patients,25 TNF-a production
by peripheral monocytes was enhanced in patients with
weight loss,26 and the elevated blood inflammatory cyto-
kine level, such as IL-6 and IL-8, has also been pointed out
to be one of the causes of metabolic enhancement in COPD
patients with malnutrition.1,2 Moreover, TNF-a was re-
ported to be involved in the induction of skeletal muscle
cell apoptosis.3 The reduction of FFM lowers exercise
tolerance and serves as a poor prognostic factor and the
association of a high cytokine level with low muscle mass
and muscle strength has been reported.27
COPD is characterized by a specific pattern of inflam-
mation involving neutrophils, macrophages, and lympho-
cytes.28 These cells release inflammatory mediators such asIL-6, IL-8, and TNF-a and interact with structural cells in
both the lung and airway.29 Our data demonstrate signifi-
cant increases in the levels of IL-6 and IL-8 in patients with
COPD, and these data are in line with previous
studies.1,2,30,31 We have shown that the levels of elevated
inflammatory cytokines decreased significantly after inter-
vention with an anti-inflammatory nutrition combined with
the low-intensity exercise in this study. We used an anti-
inflammatory nutritional supplement in which whey
peptides are enriched in this study. Whey protein, a protein
complex derived from milk, includes a-lactalbumin, lacto-
ferrin, b-lactoglobulin, glycomacropeptide, and immuno-
globulins, and has the ability to act as an antioxidant,
antitumor, and antiviral agent in vitro and in vivo.19
a-Lactalbumin32,33 and lactoferrin,34,35 components of
whey peptide, have recently been shown to inhibit
production of the inflammatory cytokines such as TNF-a and
IL-6 in rat or human monocytes. Whey protein supplemen-
tation has also been shown to have salient hep-
atoprotective effects on D-galactosamine-induced hepatitis
in rats by inhibition of IL-b and IL-6.36 Thus, taking these
findings together, it has been suggested that the positive
result in increasing the body weight and improving exercise
tolerance and HRQOL in this study were attributable mainly
to the anti-inflammatory effect of whey peptide in
Effect of anti-inflammatory supplementation with whey peptide 1533nutritional support. Our data are in line with the recent
nutritional study7 in which pressurized whey was used.
However, inflammatory cytokines and oxidant/antioxidant
markers had not been decreased significantly in the
previous study. There were two possible explanations of the
difference between our study and the previous study:
(1) different components of whey peptide were employed
between the two studies, and (2) low-intensity exercise
therapy was used in our study while high-intensity exercise
in the previous study. First as whey protein in our study
includes a-lactalbumin, lactoferrin, b-lactoglobulin, glyco-
macropeptide, and immunoglobulins which might inhibit
production of inflammatory cytokines. Second the intensity
of the exercise therapy which was used in our study was
low, while the intensity of exercise therapy in the previous
study was so high that oxidative stress might have been
induced. In order to resolve these questions, it is necessary
to verify which component of whey is essential to inhibit
inflammatory cytokines in nutritional support. Thus,
a multicenter clinical study involving an increased number
of patients is warranted to verify the effectiveness of whey
peptide in anti-inflammatory nutritional supplementation
therapy in the near future.
Many researchers consider that nutritional supplemen-
tation alone is ineffective for body weight gain and func-
tions in COPD,1,2,6 showing that muscle strength training
followed by planned nutritional supplementation is the best
possible method to increase muscular protein content.
Human skeletal muscle has been shown to be one of the
main sources of IL-6, and muscle-derived IL-6 stimulates
CRP production in the liver.37,38 It has recently been shown
that exercise-induced muscle-derived IL-6 is reduced after
low-intensity endurance training.39 Taking these findings
together, our data showing inhibition of IL-6 and CRP, after
3-month intervention with an anti-inflammatory nutritional
support and low-intensity exercise training, suggest that
inhibition might have occurred, at least in part, in the
skeletal muscle, not in the lung or the airway.
It has been shown that a habitual exercise program
prevented an increase in oxidative stress40 and muscle
strength training reduced the cytokine level in elderly
persons.41
The recent average life span in men is 80 years old in
men and 86 years old in women in Japan. Accordingly, the
age of COPD patients is higher in Japan. Exercise therapy to
maintain or increase the muscle mass should be considered
to reduce a high inflammatory cytokine level in COPD
patients, who are mostly elderly. To maintain or increase
the muscle mass, in addition to active muscle strength
training, nutritional supplementation by the ingestion of
protein and carbohydrates is indicated.42,43 The combina-
tion of muscle strength training and nutritional supple-
mentation increases the net acquired protein balance
(skeletal muscle protein synthesis-skeletal muscle prote-
olysis),44 which may increase the body weight accompanied
by an increase in FFM and improve physical function in
COPD patients.45 In elderly COPD patients who are likely to
lose weight owing to an increase in the energy expenditure
and a decrease in the energy intake over the disease
course, skeletal muscle dysfunction may reduce exercise
tolerance and influence the HRQOL. If the effect of
pulmonary rehabilitation is partially due to body weightgain induced by nutritional therapy, and recovery of the
skeletal muscle function and exercise tolerance is
promoted by exercise therapy, the combination of anti-
inflammatory nutritional supplementation and low-
intensity exercise may be an effective treatment.
On the basis of the above findings, the combination of
anti-inflammatory nutritional supplementation therapy
using nutritional support containing whey peptide with an
anti-inflammatory effect and low-intensity exercise may
not only promote body weight gain by nutritional supple-
mentation but also improve exercise tolerance and HRQOL
by inhibiting systemic inflammation in stable COPD patients
with %IBW <110% and %FEV1 <80%. The sample size and the
time period used in our study were insufficient to reach
a definitive conclusion. We believe that a study on a larger
scale and for a longer period of time should be conducted
to assess the effectiveness of anti-inflammatory nutritional
supplementation with whey peptide and low-intensity
exercise during rehabilitation in patients with COPD.
Conclusion
Although no definitive evidence for the usefulness of
nutritional supplementation therapy has been established,
our clinical study results suggested that additional anti-
inflammatory nutritional supplementation therapy with
whey peptide for stable elderly COPD patients (%IBW
<110%, %FEV1 <80%) under low-intensity exercise therapy
may improve exercise tolerance and the HRQOL by inhib-
iting systemic inflammation as an additive effect. The
effect of the combination of anti-inflammatory nutritional
supplementation and low-intensity exercise therapies may
be worth closely investigating through a clinical study
involving a large number of cases.
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